by

Johnson & Johnson to seek FDA authorization for booster shot this week, report says

The company last month said it provided additional data to the FDA.

Johnson & Johnson plans to seek emergency authorization this week for a booster dose of its COVID-19 vaccine from the US Food and Drug Administration, according to a report Monday from The New York Times. 

Last month, Johnson & Johnson said that a booster dose of its vaccine, given two months after the first shot, was 94% protective against symptomatic COVID-19 in the US and 100% effective against severe COVID-19, which puts it in the same league as its mRNA cousins, Pfizer and Moderna. Johnson & Johnson said it had given additional data to the FDA, which gave emergency use authorization for one dose of the company’s vaccine in February.

Read Full Story

Comment

Leave a Reply

Your email address will not be published.